Siltuximab is a monoclonal antibody used to treat a type of lymphoma (a type of cancer of the lymph nodes) called multicentric Castleman's disease (MCD). It works by blocking the activity of a protein called interleukin-6 (IL-6) which is involved in the growth and spread of MCD cells. Siltuximab is given as an intravenous (IV) infusion. It is approved for use in adults and is usually given as part of a combination treatment regimen. Common side effects include fever, chills, joint pain, nausea, and headache.
Siltuximab, sold under the brand name Sylvant, is a chimeric monoclonal antibody medication used to treat multicentric Castleman's disease (MCD) in people who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Siltuximab works by blocking the action of interleukin-6 (IL-6), a protein that plays a role in the immune system. In people with MCD, IL-6 levels are high, which can lead to symptoms such as fever, fatigue, and swollen lymph nodes. By blocking IL-6, siltuximab can help to improve symptoms and slow the progression of the disease.
Siltuximab is given as an injection into a vein (intravenously) by a healthcare professional. It is usually given once every 3 weeks. Siltuximab can cause side effects, including infusion reactions, upper respiratory tract infections, headache, and fatigue.